Have any questions? 706-721-6582 or cts@augusta.edu
Study Name | Principal Investigator |
---|---|
A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis | Kutlar, Abdullah |